semaglutide drowsiness and fatigue If you're worried about side effects — you're not alone. That's why Does Semaglutide Make You Tired?

That is how underappreciated this company is

Discuss with your doctor how frequently you should have A1C testing, which is usually every 3 to 6 months

[DOI] [PubMed] [Google Scholar] 102.Butler P.C., Elashoff M., Elashoff R., Gale E.A

FDA Approves Awiqli (insulin icodec-abae) as the First and Only Once-Weekly Basal Insulin Treatment for Adults with Type 2 Diabetes PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes.1 This new approval offers the only onceweekly basal insulin option, recognizing the importance of personalized care and the need for treatments that fit different patient routines and preferences for adults living with type 2 diabetes.1,2 Awiqli (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 Awiqli offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week1 The Awiqli approval reflects Novo Nordisk's ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes "Awiqli is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes

Comorbidities, meds, and customization Medical history matters more than brand names

Siddeeque N, et al